From the publishers of JADPRO

Graft-vs.-Host Disease Resource Center

Advertisement

Effective treatment of low-risk acute GVHD with itacitinib monotherapy

Last Updated: Friday, July 17, 2026

Results from a multicenter, phase 2 trial demonstrate that itacitinib monotherapy is as effective as systemic corticosteroids in treating low-risk acute GVHD with fewer serious infections.

Blood
Advertisement
News & Literature Highlights
Advertisement
Advertisement